Heat Biologics, Inc. announced the appointment of Damien Hallet as Vice President of Chemicals, Manufacturing and Controls. Hallet was promoted from his previous position as Senior Director of CMC. In this new role, he will be responsible for all aspects of development and manufacturing for the company's whole cell cancer immuno-therapy materials currently in clinical trials. He will also oversee the further development of the PTX-25 antibody from Heat's Pelican Therapeutics subsidiary. Hallet has 17 years experience working in cell therapy and antibody development for such companies as Sanofi, Gencell SAS and UCB Pharma.